Citadel Advisors LLC 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:47 pm Sale | 2026-03-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 13 0.000% | -1,721,854 (-100.00%) | Filing |
| 2025-11-21 5:36 pm Purchase | 2025-11-14 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,721,867 5.500% | 180,502 (+11.71%) | Filing |
| 2025-11-14 4:07 pm Sale | 2025-09-30 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,541,365 4.900% | -354,253 (-18.69%) | Filing |
| 2025-05-15 5:24 pm Purchase | 2025-03-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,895,618 6.000% | 245,954 (+14.91%) | Filing |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,649,664 7.400% | 15,515 (+0.95%) | Filing |
| 2023-02-14 08:02 am Sale | 2022-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,634,149 7.800% | -488 (-0.03%) | Filing |
| 2022-11-21 4:01 pm Purchase | 2022-11-09 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,634,637 7.800% | 1,634,637 (New Position) | Filing |